The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Nanoscope has received a new patent ( US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for the company ...

Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

A custom 30 G needle with a closed tip and side port shows equivalent performance to standard needles for anti-VEGF delivery.

Novel capsid technology to enable convenient delivery in the doctor's office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease Ikarovec Ltd, which is devel ...

Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to ...